We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Placental MicroRNAs Diagnosis Pregnancy Progress and Fetal Distress

By LabMedica International staff writers
Posted on 28 Sep 2021
Print article
Image: Schematic view of the placenta (Photo courtesy of Wikimedia Commons)
Image: Schematic view of the placenta (Photo courtesy of Wikimedia Commons)
Analysis of placental microRNAs (miRNAs), which also circulate in the maternal blood, represents a significant improvement to currently used pregnancy screening tools, allowing assessment of placental health, and therefore fetal health, in real time.

The critical role of the placenta in successful pregnancy is clear, and there is also evidence linking developmental programming of chronic adult disease such as heart disease, diabetes, and obesity with the placental phenotype in utero. However, there are currently no non-invasive tests to determine which women are likely to develop pregnancy complications in routine use, nor is there a comprehensive reference set of miRNA expression during early pregnancy that can be used for development of pregnancy health biomarkers.

MiRNAs comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia and cardiovascular conditions.

Investigators at Flinders University (Adelaide, Australia) generated miRNA profiles using 96 placentas from presumed normal pregnancies, across early gestation, in combination with matched profiles from maternal plasma. Placenta samples ranged from six to 23 weeks’ gestation, a time period that included placenta from the early, relatively low but physiological (six to10 weeks’ gestation) oxygen environment, and later, physiologically normal oxygen environment (11 to 23 weeks’ gestation).

The results identified 637 miRNAs with expression in 86 samples. Of these, 374 were differentially expressed (DE) miRNAs between placentas from six to10 weeks’ versus 11 to 23 weeks’ gestation. Proportional change in expression of placenta-specific miRNA clusters was reflected in maternal plasma. In particular, the amount of a cluster of miRNAs from Chromosome 19, which are only made by the placenta and are present in maternal blood, changed in response to the initiation of maternal blood flow into the placenta after 10 weeks of gestation.

"Our group has had a long-term interest in developing screening tests to identify pregnant women early in pregnancy who are at risk of pregnancy complications," said senior author Dr. Claire Roberts, professor of medicine and public health at Flinders University. "The earlier we can identify those at risk the earlier we can implement extra clinical monitoring and prevention strategies."

The placenta miRNA study was published in the August 19, 2021, online edition of the journal RNA Biology.

Related Links:
Flinders University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.